Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Oramed Pharmaceuticals (ORMP) EBIAT (2016 - 2026)

Oramed Pharmaceuticals filings provide 14 years of EBIAT readings, the most recent being $29.3 million for Q4 2025.

  • Quarterly EBIAT rose 388.63% to $29.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $77.6 million through Dec 2025, up 507.76% year-over-year, with the annual reading at $64.0 million for FY2025, 435.87% up from the prior year.
  • EBIAT hit $29.3 million in Q4 2025 for Oramed Pharmaceuticals, down from $48.4 million in the prior quarter.
  • Across five years, EBIAT topped out at $48.4 million in Q3 2025 and bottomed at -$23.0 million in Q3 2021.
  • Average EBIAT over 5 years is $21000.0, with a median of -$3.4 million recorded in 2023.
  • The largest annual shift saw EBIAT skyrocketed 801.6% in 2024 before it plummeted 597.53% in 2025.
  • Oramed Pharmaceuticals' EBIAT stood at -$23.0 million in 2021, then surged by 46.69% to -$12.3 million in 2022, then soared by 208.82% to $13.3 million in 2023, then plummeted by 176.15% to -$10.2 million in 2024, then surged by 388.63% to $29.3 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's EBIAT are $29.3 million (Q4 2025), $48.4 million (Q3 2025), and $7.5 million (Q2 2025).